Osteoporosis is weakening of bones due to lower
bone mass resulting in and micro-architectural deterioration of bone tissue and
subsequent higher risk of a broken fracture. It generally occurs at an advanced
age and women are more susceptible to it than males by about three to four
folds. WHO estimates that around 1.66 million hip fractures occur each year
worldwide due to osteoporosis. According to national osteoporosis foundation
about 54 million Americans suffer from osteoporosis.
The
disease also has a genetic bias in that it Caucasians are more affected than
Asians. The disease prevalence is lowest in African population.
The
market driving factors were identified to be rise in the geriatric population,
increased screening, drug induced osteoporosis, alcoholism and smoking,
increased awareness and focus towards female health, rising prevalence of
diseases, conditions and medical procedures that may cause bone loss such as
cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle
etc.
The
market restraints are loss of patents of block busters, greater penetration of
generics and fragmentation of market, poor efficacy and side effects of present
therapies, non-life threatening nature and poor symptoms of osteoporosis etc.
Taking
all the factors into consideration, we expect the global osteoporosis market
which totaled ~ $10,855 million to reach 14,300 million by 2022, growing with a
CAGR of 4.7%.
Key Players:
Eli Lilly and Company
Merck & Co.
Novartis International AG
Amgen Inc.
F. Hoffmann La Roche Ltd.
Pfizer Inc.
Novo Nordisk
Teva Pharmaceutical Industries
Ltd
Segmentation:
Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.
Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.
Regional
Analysis
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.
Browse Complete 84 Pages Premium Research Report Enabled with Respective
Tables and Figures @ https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479
Detailed
Table of Contents:
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power Of Suppliers
4.1.2 Bargaining Power Of Customer
4.1.3 Intensity Of Competitor’s
4.1.4 Threat Of New Entrants
5 Global Osteoporosis Drugs Market, By Drug Class
5.1 Introduction
5.2 Bisphosphonates
5.3 Calcitonins
5.4 Selective Estrogen Receptor Modulators (SERMs)
5.5 Parathyroid Hormone (PTH
5.6 Others
...Continued
About US:
Market Research Future (MRFR), enable customers
to unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment